Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Summary
Inoue J et al.  
Left Atrial Ejection Force (LAEF) in Patients With Hypertension: LAEF Is Decreased in Hypertensive Patients With Left Ventricular Failure Or Atrial Fibrillation

Journal of Clinical and Basic Cardiology 2002; 5 (3): 237-240

PDF    Summary    Figures   

Fig. 1: LAEF (Left Atrial Ejection Force) Fig. 2: LAEF (left atrial ejection force) - Alter Fig. 3: LAEF (left atrial ejection force) - Herzmasse Fig. 4: LAEF (left atrial ejection force) - Linksatrialer Durchmesser Fig. 5: LAEF (left atrial ejection force) - WHO-Klassifikation Fig. 6: LAEF (left atrial ejection force) - Hypertonie Fig. 7: LAEF (left atrial ejection force) - Hypertonie Last Image



Keywords: dekompensierte HerzinsuffizienzHypertonieKardiologielinksartiale Kontraktionlinksartriale AuswurfkraftVorhofflimmernatrial fibrillationcongestive heart failurehypertensionleft atrial contractionleft atrial ejection force

Background: Left atrial (LA) contraction is an important parameter in hypertensive (HT) patients. However, it is difficult to evaluate LA contraction non-invasively. Recently, a Doppler echocardiogram derived left atrial ejection force (LAEF) method was introduced for evaluating LA contraction. We studied LAEF in patients with HT. Subjects: One hundred and twenty-four patients with HT were studied. There were 74 men and 50 women. Age ranged 35-77 years. Thirty-five normal subjects and 20 patients with congestive heart failure (CHF) or paroxysmal atrial fibrillation (PAF) were also studied. Principle: According to Newton’s law of motion, LAEF is calculated as LA ejection volume x acceleration of flow. LA ejection volume = mitral valve area (MVA) x time velocity integral of mitral flow. Acceleration is the slope of atrial flow velocity. Methods: (1) MVA was calculated by 2-D echo. Mitral flow velocity was recorded by pulsed Doppler. (2) LAEF was calculated as 1/3 x MVA x A2, where A is the atrial flow velocity. (3) LAEF was compared with WHO stage and period of HT. (4) LAEF was compared between patients with and without CHF or PAF. Results: (1) In normal subjects, LAEF correlated with age (r = 0.74, p < 0.001). Therefore, age corrected %LAEF was used for analysis. %LAEF = (actual LAEF) / (normal LAEF) x 100. (2) In patients with HT, %LAEF was 107.8 ± 5.7 % in WHO stage I, 111.6 ± 8.0 % in stage II and 105.7 ± 13.5 % in stage III (n.s.). %LAEF was higher in patients with WHO stage I and II than normal subjects. (3) %LAEF was 111.6 ± 6.0 % in patients with period < 9 years, 108.6 ± 9.0 % in period 10–20 years and 105.8 ± 11.2 % in period > 20 years. %LAEF had a tendency to decrease with period of HT (n.s.). (4) %LAEF was 50.5 ± 22.4 % in patients with PAF, and was 64.3 ± 31.8 % in patients with CHF. %LAEF was lower in hypertensive patients with CHF or PAF than without CHF or PAF (p < 0.001). Conclusions: LAEF may be compensated in mid stage of hypertension and decompensated in late stage of hypertension. LAEF is decreased in hypertensive patients with paroxysmal atrial fibrillation or congestive heart failure.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung